Managing a tachyarrhythmia in a patient with pheochromocytoma with landiolol, a novel ultrashort-acting β-adrenergic blocker [6]

Anesthesia and Analgesia

Volumn 97, Issue 1, 2003, Pages 294-295

  Ogata, Junichi ^a   Yokoyama, Toru ^a   Okamoto, Takashi ^a   Minami, Kouichiro ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FENTANYL; LANDIOLOL; NICARDIPINE; NITROUS OXIDE; ROPIVACAINE; SEVOFLURANE;

ADULT; CANCER SURGERY; CASE REPORT; DRUG EFFICACY; ELECTROCARDIOGRAM; FEMALE; HUMAN; HYPERTENSION; INTRAOPERATIVE PERIOD; LETTER; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; TACHYCARDIA;

EID: 0037974325     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ane.0000067919.62656.73     Document Type: Letter

References (3)

1. Nicholas E, Deutschman CS, Allo M, Rock P. Use of esmolol in the intraoperative management of pheochromocytoma. Anesth Analg 1988;67:1114-7.
2. Atarashi H, Kuruma A, Yashima M, et al. Pharmacokinetics of landiolol hydrochloride, a new ultra-short-acting beta-blocker, in patients with cardiac arrhythmias. Clin Pharmacol Ther 2000;68:143-50.
3. Muraki K, Nakagawa H, Nagano N, et al. Effects of ONO-1101, a novel beta-antagonist, on action potential and membrane currents in cardiac muscle. J Pharmacol Exp Ther 1996;278:555-63.